TD Cowen has initiated coverage on Kiniksa Pharmaceuticals International PLC (KNSA) with a Buy rating as of September 28, 2025. This marks the firm’s first assessment of Kiniksa's investment potential, reflecting their research and analysis of the company's operations, industry dynamics, and growth prospects.
Kiniksa, a commercial-stage biopharmaceutical company based in Great Britain, focuses on developing innovative treatments for various conditions. Its portfolio includes ARCALYST, which is used for treating recurrent pericarditis and certain autoinflammatory syndromes. The company also has investigational assets like Mavrilimumab, which targets granulocyte-macrophage colony stimulating factor receptor alpha.
As of now, Kiniksa's shares are trading at $41.74, with a market capitalization of $3.1 billion. The company has a trailing P/E ratio of 87.55 and an EPS of 0.45. Upcoming earnings reports are anticipated, with estimates of $0.41 per share on revenue of $226.9 million set for July 27, 2026.
Analyst ratings serve as professional opinions shaped by extensive research and financial modeling. While they can provide valuable insights, these assessments are based on assumptions that may not always hold true. Investors are encouraged to consider a range of factors, including company fundamentals and market conditions, when making decisions. Analyst ratings can evolve as new information becomes available, and varying opinions may exist across different analysts.